Literature DB >> 31985

Prospects for the prevention of bacterial meningitis with polysaccharide vaccines.

E C Gotschlich, R Austrian, B Cvjetanović, J B Robbins.   

Abstract

MOST SUPPURATIVE INFECTIONS OF THE MENINGES ARE CAUSED BY FIVE BACTERIAL SPECIES: Escherichia coli, Haemophilus influenzae type b, Streptococcus pneumoniae, Neisseria meningitidis, and group B streptococcus. The immune response of adults to pneumococcal capsular polysaccharides has been studied in great detail and their responses to meningococcal and H. influenzae type b capsular polysaccharides are quite similar. Immune responses of adults to E. coli and group B streptococcal antigens are disappointing. The responses of children below the age of 7 years differ both quantitatively and in duration. Early experience shows that useful antibody titres can be achieved with certain antigens but further studies are required. In order to prevent bacterial meningitis by immunization, three vaccine formulations will need to be developed. When epidemic meningococcal disease occurs in a population, the vaccine containing only components of the meningococcus would be applied to a large segment of the population to terminate the epidemic. The second vaccine would contain components of H. influenzae type b, pneumococcus, and the meningococcus and would be administered in the first year of life, and repeated at suitable intervals to maintain life-long immunity. The third vaccine, designed to prevent neonatal meningitis caused by E. coli K1 and group B streptococci, would be administered to women preferably during the third trimester of pregnancy, so that their offspring would inherit sufficient antibodies to protect them during the first 3 months of life.The vaccine against the meningococcus is a reality and has been used extensively during major epidemics, with excellent results. The two vaccines for control of endemic bacterial meningitides do not exist as yet, but the prospects are good.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 31985      PMCID: PMC2395652     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  3 in total

Review 1.  Group B streptococci in human disease.

Authors:  M J Patterson; A El Batool Hafeez
Journal:  Bacteriol Rev       Date:  1976-09

2.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

3.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

  3 in total
  12 in total

1.  Splenectomy... for trauma.

Authors:  R E Falk
Journal:  Can Med Assoc J       Date:  1979-07-07       Impact factor: 8.262

2.  Interaction of Neisseria meningitidis with human dendritic cells.

Authors:  A Kolb-Mäurer; A Unkmeir; U Kämmerer; C Hübner; T Leimbach; A Stade; E Kämpgen; M Frosch; G Dietrich
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

3.  Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.

Authors:  E C Beuvery; F Miedema; R van Delft; J Haverkamp
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

4.  [An epidemiological study of purulent meningitis cases admitted to hospital in Dakar, 1970-1979].

Authors:  M Cadoz; F Denis; I D Mar
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

5.  Streptococcal infection in young pigs. V. An immunogenic polysaccharide from Streptococcus suis type 2 with particular reference to vaccination against streptococcal meningitis in pigs.

Authors:  S D Elliott; F Clifton-Hadley; J Tai
Journal:  J Hyg (Lond)       Date:  1980-10

6.  Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates.

Authors:  E C Beuvery; F van Rossum; J Nagel
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

7.  Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of Neisseria meningitidis.

Authors:  E C Beuvery; F Miedema; R W van Delft; J Haverkamp; A B Leussink; B J te Pas; K S Teppema; R H Tiesjema
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

8.  Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice.

Authors:  E C Beuvery; R W van Delft; F Miedema; V Kanhai; J Nagel
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

9.  Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine.

Authors:  F Ambrosch; G Wiedermann; P Crooy; A M George
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

10.  Studies of Streptococcus suis type 2 infection in pigs.

Authors:  F A Clifton-Hadley
Journal:  Vet Res Commun       Date:  1984-08       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.